
Delaware-based Surface Pharmaceuticals develops biotech solutions for dry eye diseases, serving California.
Surface Pharmaceuticals, founded in Delaware, is a biotechnology company dedicated to developing innovative treatments for dry eye diseases. The company's core mission is to improve the quality of life for individuals suffering from ocular surface conditions through advanced medical solutions. Surface Pharmaceuticals focuses on creating and distributing cutting-edge medications and therapies specifically targeting dry eye diseases, with a primary market focus in California.
Notable affiliated individuals include key leaders in biotechnology and ophthalmology, though specific names are not provided. The company has achieved significant milestones in drug development and clinical trials, contributing to advancements in eye care. Surface Pharmaceuticals' impact is marked by its commitment to addressing unmet medical needs in ocular health, positioning itself as a crucial player in the biotech industry for eye disease treatment.

Surface Ophthalmics

TearClear
tearclear.com

MediPrint Ophthalmics

TearSolutions
tearsolutions.com

Ocular Science
ocularscience.com

EyePoint

EyeCyte
eyecyte.com

Ocular Therapeutix
ocutx.com

Sight Sciences
sightsciences.com

Visiox
visioxpharma.com

Ocuphire Pharma
ocuphire.com

Replenish

Ocumension Therapeutics

Seeing Medicines

OcuCure Therapeutics
Companies similar to Surface Pharmaceuticals include Surface Ophthalmics, TearClear, MediPrint Ophthalmics and TearSolutions.
Surface Pharmaceuticals was founded in 2017.
Surface Pharmaceuticals' headquarters is located in Delaware, US.
Surface Pharmaceuticals' most recent funding round was for $5.8M (USD) in June 2021.
As of Jun 10, 2021, Surface Pharmaceuticals has raised a total of $46.8M (USD).
Surface Pharmaceuticals has 8 employees as of Feb 4, 2024.